OncoGenex shares jump on trial plans

Shares of Bothell, WA-based OncoGenex jumped on the news that it's planning to proceed with late-stage trials of a prostate cancer therapy dubbed OGX-011. The company earned some kudos from Rodman & Renshaw analyst Simos Simeonidis, who said "We would like to point out that this is a very small team that got to the point where many biotechs dream of." Shares rose about 15 percent. Report

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.